The role of multiparameter flow cytometry for disease monitoring in AML

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 3, 2010, Pages 379-390

  Kern, Wolfgang ^a   Bacher, Ulrike ^b   Haferlach, Claudia ^a   Schnittger, Susanne ^a   Haferlach, Torsten ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Acute myeloid leukemia (AML); Minimal residual disease (MRD); Multiparameter flow cytometry (MFC); Polymerase chain reaction (PCR); Remission

Indexed keywords

CD45 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; MULTIPARAMETER FLOW CYTOMETRY; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT;

FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; PROGNOSIS;

EID: 78649521002     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2010.06.007     Document Type: Review

References (61)

1. T. Büchner, W. Hiddemann, and B. Wormann Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group Blood 93 1999 4116 4124
2. B. Lowenberg, W. van Putten, and M. Theobald Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia N Engl J Med 349 2003 743 752
3. W. Kern, T. Haferlach, and C. Schoch Risk-adapted therapy of AML: the AMLCG experience Ann Hematol 83 Suppl. 1 2004 S49 S51
4. B.D. Cheson, J.M. Bennett, and K.J. Kopecky Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia J Clin Oncol 21 2003 4642 4649
5. R.F. Schlenk, K. Döhner, and J. Krauter Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1909 1918
6. J. Koreth, R. Schlenk, and K.J. Kopecky Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials JAMA 301 2009 2349 2361
7. U. Bacher, C. Haferlach, and S. Schnittger Interactive diagnostics in the indication to allogeneic SCT in AML Bone Marrow Transplant 43 2009 745 756
8. S. Schnittger, M. Weisser, and C. Schoch New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts Blood 102 2003 2746 2755
9. G. Marcucci, M.A. Caligiuri, and H. Döhner Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia Leukemia 15 2001 1072 1080
10. D. Grimwade, K. Howe, and S. Langabeer Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse Leukemia 10 1996 61 66
11. S. Schnittger, W. Kern, and C. Tschulik Minimal residual disease levels assessed by NPM1 mutation specific RQ-PCR provide important prognostic information in AML Blood 114 2009 2220 2231
12. D.M. Bahia, M. Yamamoto, and M.L. Chauffaille Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical significance Haematologica 86 2001 801 806
13. W. Kern, D. Voskova, and C. Schoch Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia Blood 104 2004 3078 3085 (Pubitemid 39517010)
14. J.F. San Miguel, M.B. Vidriales, and C. Lopez-Berges Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification Blood 98 2001 1746 1751
15. F. Buccisano, L. Maurillo, and V. Gattei The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia Leukemia 20 2006 1783 1789
16. M.R. Loken, V.O. Shah, and K.L. Dattilio Flow cytometric analysis of human bone marrow: I. Normal erythroid development Blood 69 1987 255 263
17. M.R. Loken, V.O. Shah, and K.L. Dattilio Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development Blood 70 1987 1316 1324
18. L.W. Terstappen, M. Safford, and M.R. Loken Flow cytometric analysis of human bone marrow. III. Neutrophil maturation Leukemia 4 1990 657 663
19. P. Lucio, A. Parreira, and M.W. van den Beemd Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL Leukemia 13 1999 419 427
20. L.W. Terstappen, S. Huang, and M. Safford Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+ Blood 77 1991 1218 1227
21. E.L. Sievers, B.J. Lange, and T.A. Alonzo Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia Blood 101 2003 3398 3406
22. C.L. Reading, E.H. Estey, and Y.O. Huh Expression of unusual immunophenotype combinations in acute myelogenous leukemia Blood 81 1993 3083 3090
23. A. Macedo, A. Orfao, and J. Ciudad Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease Leukemia 9 1995 1896 1901
24. F. Buccisano, L. Maurillo, and A. Spagnoli Monitoring of minimal residual disease in acute myeloid leukemia Curr Opin Oncol 21 2009 582 588
25. A. Al-Mawali, D. Gillis, and I. Lewis The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia Am J Clin Pathol 131 2009 16 26
26. K. Nakamura, K. Ogata, and E. An Flow cytometric assessment of CD15+CD117+ cells for the detection of minimal residual disease in adult acute myeloid leukaemia Br J Haematol 108 2000 710 716
27. W. Kern, D. Voskova, and C. Schoch Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia Haematologica 89 2004 528 540
28. A. Al-Mawali, D. Gillis, and P. Hissaria Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry Am J Clin Pathol 129 2008 934 945
29. E. Coustan-Smith, F.G. Behm, and C.A. Hurwitz N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia Leukemia 7 1993 853 858
30. D. Campana, and E. Coustan-Smith Detection of minimal residual disease in acute leukemia by flow cytometry Cytometry 38 1999 139 152
31. A. Venditti, F. Buccisano, and G. Del Poeta Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia Blood 96 2000 3948 3952
32. A. Al-Mawali, D. Gillis, and I. Lewis The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse Cytometry B Clin Cytom 76 2009 91 101
33. W. Kern, T. Haferlach, and C. Schoch Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial Blood 101 2003 64 70
34. G. Gianfaldoni, F. Mannelli, and M. Baccini Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study Br J Haematol 134 2006 54 57
35. E. Coustan-Smith, R.C. Ribeiro, and J.E. Rubnitz Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia Br J Haematol 123 2003 243 252
36. C. Langebrake, U. Creutzig, and M. Dworzak Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group J Clin Oncol 24 2006 3686 3692
37. H.M. Kantarjian, M.J. Keating, and R.S. Walters The characteristics and outcome of patients with late relapse acute myelogenous leukemia J Clin Oncol 6 1988 232 238
38. W. Kern, T. Haferlach, and S. Schnittger Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy Leukemia 16 2002 2084 2091
39. U. Oelschlagel, R. Nowak, and A. Schaub Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia Cytometry 42 2000 247 253
40. D. Voskova, C. Schoch, and S. Schnittger Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings Cytometry B Clin Cytom 62 2004 25 38
41. A. Macedo, J.F. San Miguel, and M.B. Vidriales Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease J Clin Pathol 49 1996 15 18
42. M.R. Baer, C.C. Stewart, and R.K. Dodge High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361) Blood 97 2001 3574 3580
43. C. Langebrake, I. Brinkmann, and A. Teigler-Schlegel Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring Cytometry B Clin Cytom 63 2005 1 9
44. V.O. Shah, C.I. Civin, and M.R. Loken Flow cytometric analysis of human bone marrow. IV. Differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis J Immunol 140 1988 1861 1867
45. M.J. Borowitz, K.L. Guenther, and K.E. Shults Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis Am J Clin Pathol 100 1993 534 540
46. J. Logan, K. Edwards, and N. Saunders Real-time PCR: current technology and applications 2009 Caister Academic Press Norfolk, UK
47. R.E. Gallagher, B.Y. Yeap, and W. Bi Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129 Blood 101 2003 2521 2528
48. J. Krauter, K. Gorlich, and O. Ottmann Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias J Clin Oncol 21 2003 4413 4422
49. B. Falini, C. Mecucci, and E. Tiacci Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype N Engl J Med 352 2005 254 266 (Pubitemid 40110814)
50. E. Barragan, J.C. Pajuelo, and S. Ballester Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression Clin Chim Acta 395 2008 120 123
51. U. Bacher, A. Badbaran, and B. Fehse Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation Exp Hematol 37 2009 135 142
52. B. Falini, P. Sportoletti, and M.P. Martelli Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives Curr Opin Oncol 21 2009 573 581
53. H.B. Ommen, C.G. Nyvold, and K. Braendstrup Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals Br J Haematol 141 2008 782 791
54. G. Perea, A. Lasa, and A. Aventin Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)] Leukemia 20 2006 87 94
55. J. Stentoft, P. Hokland, and M. Ostergaard Minimal residual core binding factor AMLs by real time quantitative PCR-initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse Leuk Res 30 2006 389 395
56. S. Viehmann, A. Teigler-Schlegel, and J. Bruch Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement Leukemia 17 2003 1130 1136
57. W. Kern, S. Dannhauser-Riedl, and R. Ratei Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow Haematologica 88 2003 646 653
58. A. Nagler, R. Condiotti, and R. Rabinowitz Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC) Med Oncol 16 1999 177 187
59. W. Kern, D. Voskova, and S. Schnittger Early assessment of minimal residual disease by multiparameter flow cytometry identifies patients at high risk of relapse after allogeneic stem cell transplantation following reduced intensity conditioning for advanced acute myeloid leukemia. Annual meeting of the American Society of Hematology 2003 Blood 102 2003 874a
60. D.A. Wells, G.E. Sale, and H.M. Shulman Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation Am J Clin Pathol 110 1998 84 94
61. J.A. Perez-Simon, D. Caballero, and M. Diez-Campelo Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation Leukemia 16 2002 1423 1431